Former Axiom science lead launches Warp Science to automate wet labs with robots

Kevin Weil, formerly Axiom’s science lead, launched Warp Sciences as an AI startup for drug discovery. The company focuses on automating physical laboratory work, not just analyzing scientific data. Its robots will make and test promising chemical compounds identified by researchers.

The central example is molecule synthesis and testing. Researchers may identify promising compounds, then need many related versions made and evaluated. Warp Sciences plans to train robots for these tasks, allowing machines to repeat laboratory procedures consistently and operate around the clock.

The company has raised $215 million at an $865 million valuation. Its broader goal is to bring labor-intensive drug-development work back from overseas contractors in China. Weil also wants automation to reduce exposure to geopolitical supply-chain risks while potentially speeding up the discovery process.

A wet lab is a physical laboratory where researchers work directly with chemicals, biological materials, instruments, and samples. The name distinguishes hands-on experiments from research performed mainly with computers. Wet-lab work can include preparing substances, combining them, measuring results, and testing how materials behave.

Computer-based research uses software, mathematical models, simulations, or data analysis. For example, a computer might help identify promising compounds, while a wet lab would make those compounds and test them physically. The two approaches can support each other, but they involve different tasks.

Warp Sciences is focused on automating the physical side. Human chemists will use cameras and sensor gloves to teach robots laboratory procedures. Those robots could then repeat tasks, make compounds, and test them around the clock. The article presents this automation as a way to accelerate drug discovery.

Warp Sciences raised $215 million in funding, while investors valued the company at $865 million. These are different figures. The first is the capital invested in the round. The second is the estimated overall value assigned to the startup during that financing.

In practical terms, an $865 million valuation suggests investors believe the company and its future prospects are worth that amount at the time of the deal. It does not mean Warp Sciences received $865 million in cash. The funding round was led by Lightspeed, with participation from IVP, Mayfield, Lux Capital, Premji Invest, and Menlo Ventures.

The money supports a company attempting to automate drug-discovery laboratory work. Warp Sciences wants robots to make and test compounds, operate around the clock, and help reshore work often outsourced to contractors in China. The figures signal substantial investor backing for that plan.

Warp Sciences plans to use human chemists as demonstrations for its robots. The chemists will wear cameras and sensor gloves while carrying out different laboratory tasks. Cameras can capture what happens around the work area, while sensor gloves can record hand movements and interactions with equipment.

The key mechanism is training through observed human performance. A chemist performs a procedure, and the robot receives information about the actions involved. The article does not specify the exact hardware or software system, but it says the human chemists will train robots to perform various lab tasks.

After training, the robots are intended to handle wet-lab work themselves. They could make and test promising compounds identified by researchers and continue operating around the clock. This approach aims to reduce the amount of repetitive manual work while helping Warp Sciences speed up drug discovery and bring some outsourced work back home.

Biotech companies have outsourced the synthesis of thousands of molecule variations because the work requires extensive labor. Each variation may need to be made and tested as researchers search for promising compounds. Handling that volume can be difficult for companies to perform entirely themselves.

The article identifies contractors in China, such as WuXi AppTec, as providers of this outsourced work. These contractors have carried out the labor-intensive process of synthesizing many molecular versions. Outsourcing lets biotech companies rely on specialized external operations instead of keeping all that capacity in-house.

Warp Sciences wants to reshore this work. Its robots would perform laboratory tasks in an automated system, potentially reducing dependence on overseas contractors. Weil also hopes this approach will insulate the broader drug-development process from geopolitical supply-chain risks. The article does not say that Warp Sciences has already replaced those contractors.

Automating laboratory work could let Warp Sciences run experiments continuously instead of limiting operations to human working hours. The company says its robots may operate around the clock. That creates the possibility of processing more compound-making and testing tasks over a given period.

For example, robots could synthesize and test promising compounds identified by researchers while human chemists train the machines on laboratory procedures. The mechanism is repeated automated wet-lab work. Cameras and sensor gloves help capture how chemists perform tasks, and robots are trained to reproduce those actions.

Warp Sciences also aims to reshore work that biotech companies have outsourced to contractors in China. Weil hopes domestic automation will insulate the entire drug-development process from geopolitical supply-chain risks. The article presents these as goals, not completed outcomes. It does not provide measured results showing how much faster or cheaper the process will become.

Drug discovery is the process of finding promising chemical compounds for potential medicines. Researchers investigate compounds and test how they perform. The article describes a workflow in which researchers identify promising compounds, then companies make and test them in laboratory settings.

Scientists synthesize many variations because small changes to a molecule can produce different results. Comparing those versions gives researchers more candidates to evaluate. The article emphasizes the scale of this work, describing thousands of molecule variations and calling their synthesis labor-intensive. Testing helps determine which compounds deserve further attention.

Warp Sciences wants robots to automate this cycle. Human chemists will train robots to perform laboratory tasks using cameras and sensor gloves. The robots will then make and test promising compounds, potentially working around the clock. The stated aim is to accelerate drug discovery while reducing reliance on overseas contractors and protecting the development process from supply-chain risks.